Lentiviral particles allow easy gene delivery
Supplied ready to use
The Abingdon, UK-based firm supplies the new particles ready to use, eliminating the need for any lipids or transfection reagents. The company says these pre-made lentiviral particles are proven to deliver genes in a highly reproducible and controllable manner for the expression of more than 250 human proteins, mouse proteins, enzymes and fluorescent markers.
Using proprietary protocols based on co-expressed red fluorescent protein by a 2A peptide processing (SureTitre) or RSV promoter (Inducible system), these lentiviral particles enable real time monitoring of protein expression.
All AMSBIO lentiviral products are said to be easy and safe to use by simply adding the high titre particles (1 x 107 IFU/ml or higher) to cultured cells, and you will be able to confirm the specific target's expression under a fluorescent microscope after 48–72 hours.
AMSBIO lentiviral particles are packaged in culture medium with 10% FBS, in serum-free medium or concentrated in PBS for in vivo use.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Accelerating the development of bispecific antibodies
Read moreSherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Accelerating the development of bispecific antibodies
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering